Rhythm Biosciences Limited

As of June 30, 2026, Rhythm Biosciences Limited carries a market capitalization of 33.13M, placing it among publicly traded companies globally. Its enterprise value stands at 29.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rhythm Biosciences Limited's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Rhythm Biosciences Limited has 364.06M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 356.41, and the price-to-book ratio stands at 9.11.

These figures are as of June 30, 2026. The EV/Sales ratio of 350.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 29.94M versus a market cap of 33.13M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rhythm Biosciences Limited maintains a current ratio of 3.61, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.82, indicating elevated leverage, while an interest coverage ratio of -97.88 demonstrates limited ability to service its debt obligations.

As of the close on October 22, 2026, Rhythm Biosciences Limited's stock has declined approximately 29.47% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.13.

Over the twelve months ended June 30, 2026, Rhythm Biosciences Limited generated 85,339.00 in revenue and converted that into -5.93M in net income, yielding earnings per share of -0.02. EBITDA reached -7.32M, while operating income came in at -7.46M.

As of June 30, 2026, Rhythm Biosciences Limited holds 3.44M in cash and equivalents against 247,980.00 in total debt, resulting in a net debt position of -3.27M. Total book value stands at 3.64M, with working capital of 2.72M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Rhythm Biosciences Limited posted a gross margin of -321.80, reflecting its pricing power and cost economics. The operating margin of -8,739.15 and net profit margin of -6,948.85 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -21.78, meaning Rhythm Biosciences Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Rhythm Biosciences Limited's most recent stock split took place on February 21, 2024 with a 140:143 split ratio.

As of June 30, 2026, Rhythm Biosciences Limited has an Altman Z-Score of -5.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.